• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
PoliticsJoe Manchin

Joe Manchin tests positive for COVID-19

By
Erik Wasson
Erik Wasson
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Erik Wasson
Erik Wasson
and
Bloomberg
Bloomberg
Down Arrow Button Icon
July 25, 2022, 11:10 AM ET
Senator Joe Manchin
West Virginia Senator Joe Manchin is experiencing mild symptoms after testing positive for COVID-19. Al Drago—Bloomberg/Getty Images

West Virginia Senator Joe Manchin announced Monday that he has been diagnosed with COVID-19, the latest in a string of Democratic senators to be absent from Washington due to the highly contagious illness. 

Manchin’s diagnosis highlights the challenge Democrats will face in mustering the 50 votes they need to pass a drug price and Obamacare subsidy bill before the start of August recess next week. 

This morning I tested positive for COVID-19. I am fully vaccinated and boosted and am experiencing mild symptoms. I will isolate and follow CDC guidelines as I continue to work remotely to serve West Virginians.

— Senator Joe Manchin (@Sen_JoeManchin) July 25, 2022

Last week, Delaware Senator Tom Carper and Minnesota Senator Tina Smith announced they had contracted COVID, while Senator Richard Blumenthal and Majority Leader Chuck Schumer had the virus earlier in the month. In addition, Vermont Senator Patrick Leahy has been away from the Senate recovering from hip surgery for weeks. 

Democrats will need all 50 of their caucus members and Vice President Kamala Harris to vote to approve the party-line budget bill enacting drug price cuts and extending Obamacare premium subsidies for two years, if as expected all Republicans are present and vote no. While Manchin is likely to return to Washington next week and Leahy’s office has said he can be available for votes if needed, any further positive COVID tests among Democrats could throw the plan for the drug bill into doubt. 

Senate Democrats are waiting Monday for a ruling from the Senate parliamentarian on whether the drug bill—which allows Medicare to negotiate prices it pays for drugs for the first time and caps out of pocket costs for seniors—will be allowed in the fast-track budget process. 

A vote is planned today in the Senate to end debate on a $79 billion China competition bill that provides $52 billion in subsidies to the semiconductor industry. The legislation has bipartisan support and won 64 votes on an earlier procedural vote so Manchin’s absence is not expected to hinder its passage by the House and Senate this week. 

—With assistance from Alexander Ruoff.

Sign up for the Coins2Day Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.

About the Authors
By Erik Wasson
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.